Anupma Nayak

An Agreement Study of Stromal Cellularity, Stromal Cell Atypia, and Tumor Border of Phyllodes Tumors of the Breast

Xiaoxian Li, Yulin Haw, Yi Liu, Jabed Iqbal et autres

us, sg (code pays fourni par la source)

Figure S2 from Residual Breast Cancer Cells Co-opt SOX5-Driven Endochondral Ossification to Maintain Dormancy

Amulya Sreekumar, Eric Blankemeyer, Christopher J. Sterner, Tien-Chi Pan et autres

Supplementary Figure S2 shows Sox5 and Sox6 sgRNA editing efficiency, primary tumor and recurrent tumor growth rate at the orthotopic and metastatic site in MTB/TAN cells

Figure S5 from Residual Breast Cancer Cells Co-opt SOX5-Driven Endochondral Ossification to Maintain Dormancy

Amulya Sreekumar, Eric Blankemeyer, Christopher J. Sterner, Tien-Chi Pan et autres

Supplementary Figure S5 shows μCT and [18F]NaF PET in MTB/TAN cells as well as GFP positivity relative to Alcian blue staining

Supplementary Table S1 from Residual Breast Cancer Cells Co-opt SOX5-Driven Endochondral Ossification to Maintain Dormancy

Amulya Sreekumar, Eric Blankemeyer, Christopher J. Sterner, Tien-Chi Pan et autres

List of targets and sgRNAs used in the custom CRISPR-Cas9 screen. sgRNAs with validated editing efficiency are highlighted

Figure S1 from Residual Breast Cancer Cells Co-opt SOX5-Driven Endochondral Ossification to Maintain Dormancy

Amulya Sreekumar, Eric Blankemeyer, Christopher J. Sterner, Tien-Chi Pan et autres

Supplementary Figure S1 shows sgRNA distribution at each of the time points during disease progression as well as clonal enrichment for sgRNAs targeting Sox5 and Sox6 in MTB/TAN cells

Figure S4 from Residual Breast Cancer Cells Co-opt SOX5-Driven Endochondral Ossification to Maintain Dormancy

Amulya Sreekumar, Eric Blankemeyer, Christopher J. Sterner, Tien-Chi Pan et autres

Supplementary Figure S4 shows chondrogenesis and osteogenesis signature enrichment during dormancy in vitro in MTB/TAN cells as well as GFP positivity relative to Alcian blue staining

Figure S3 from Residual Breast Cancer Cells Co-opt SOX5-Driven Endochondral Ossification to Maintain Dormancy

Amulya Sreekumar, Eric Blankemeyer, Christopher J. Sterner, Tien-Chi Pan et autres

Supplementary Figure S3 shows Sox5 shRNA knockdown efficiency, proliferation and apoptosis rates in vitro and in vivo, and Sox5 sgRNA editing efficiency in nucleofected D2.OR cells

Data from Residual Breast Cancer Cells Co-opt SOX5-Driven Endochondral Ossification to Maintain Dormancy

Amulya Sreekumar, Eric Blankemeyer, Christopher J. Sterner, Tien-Chi Pan et autres

Abstract Recurrent breast cancer accounts for most disease-associated mortality and can develop decades after primary tumor therapy. Recurrences arise from residual tumor cells (RTC) that can evade therapy in a dormant state; however, the mechanisms enforcing dormancy in RTCs are poorly understood. …

Preoperative combination radiotherapy (RT) and immune checkpoint inhibitor (ICI) in early-stage breast cancer: Influence of RT and ICI treatment sequencing (NCT04454528 post-hoc analysis).

Julia Tchou, Anupma Nayak, He N. Xu, Jack Kollmar et autres

615 Background: The anti-tumor immune effects of combination radiotherapy (RT) and immune checkpoint inhibitors (ICI) are synergistic. Optimal treatment sequencing, i.e. RT before ICI vs. RT after ICI, remains unclear. Assuming clinical equipoise, we conducted a phase 1b/2 multi-arm adaptive window of …

us (code pays fourni par la source)

Distinct genomic and immunologic tumor evolution in germline TP53-driven breast cancers

Nabamita Boruah, David Hoyos, Renyta Moses, Ryan Hausler et autres

Pathogenic germline TP53 alterations cause Li-Fraumeni Syndrome (LFS), and breast cancer (BC) is the most common cancer in LFS females. Here, we perform a multimodal analysis, comparing LFS-BC with sporadic premenopausal breast cancer which shows that nearly all LFS-BC undergo biallelic loss …

us (code pays fourni par la source)

Comparative analysis of distinct genomic landscapes in young-onset gBRCA1/2 breast cancer

Mwangala P. Akamandisa, Mingyi Xia, Wilson Cheah, Bradley Wubbenhorst et autres

Carriers of germline BRCA1/2 pathogenic variants (gBRCA1/2 PVs) have elevated young-onset breast cancer risk. To define the pretreatment genomic landscapes of young-onset gBRCA-associated breast cancer, we evaluated 136 treatment-naive tumors diagnosed before age 50 in the prospective POSH study and 66 noncarriers …

us, gb (code pays fourni par la source)

Abstract 4966: A single-cell spatial proteomic analysis of the TNBC microenvironment defines genotype-specific features

Dana Pueschl, Danielle Bragen, Jia-Ren Lin, Anupma Nayak et autres

Abstract Breast cancer in women with germline BRCA1/2 pathogenic variants (gBRCA1/2) are generally treated with platinum-based therapies and PARP inhibitors (PARPi) with resistance commonly emerging. As the tumor microenvironment (TME) in gBRCA1 triple-negative breast cancer (TNBC) is enriched with tumor-infiltrating lymphocytes (TILs) …

us, au, my, gb (code pays fourni par la source)